USA flag logo/image

An Official Website of the United States Government

Peptide Eyedrops for Treatment of Diabetic Retinopathy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75644
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
EY016921
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CHARLESSON, LLP
800 Research Parkway OKLAHOMA CITY, OK 73104
View profile »
Woman-Owned: Yes
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Peptide Eyedrops for Treatment of Diabetic Retinopathy
Agency: HHS
Contract: 1R43EY016921-01
Award Amount: $133,750.00
 

Abstract:

DESCRIPTION (provided by applicant): Diabetic retinopathy is a common complication of diabetes and a leading cause of blindness in the US and the world. Diabetic macular edema (DME) and retinal neovascularization are the two major pathological alternations leading to the vision loss in diabetic retinopathy. The retinal vascular hyper-permeability or vascular leakage is primarily responsible for DME. Over-expression of vascular endothelial growth factor (VEGF) in the retina plays a crucial role in the BRB breakdown. Currently, there is no effective and noninvasive treatment for DME. A new, non-invasive and cost-effective treatment for DME is needed. It has been found that plasminogen kringle 5 (K5), an 80-amino acid fragment of plasminogen, has the potent anti-angiogenic activity, such as inhibiting the endothelial cell proliferation and migration, which are an important process in angiogenesis. Our previous studies have demonstrated that K5 blocks the VEGF overproduction in the retina and effectively reduces retinal vascular leakage in three independent retinopathy animal models after a single intra-ocular or peri-ocular injection of a low dose. Moreover, the effect of K5 on vascular permeability can be achieved via topical application of K5 eyedrops. These results suggest that administration of this angiogenic inhibitor should have therapeutic effect on DME. We hypothesize that the continuous topical application of K5 eyedrops may become an effective and non-invasive therapy for DME. The objective of this Phase I project is to prove the concept that the K5 eyedrop administration can have long-term therapeutic effect on vascular leakage in the retina of STZ-induced diabetic rats. To obtain the effective concentration of K5 eyedrops for blocking retinal vascular leakage in diabetic rats, we will investigate the pharmacokinetics and distribution of K5 after the administration of K5 eyedrops. Then, we will determine if continuous administration of the K5 eyedrop can result in sustained reduction of retinal vascular leakage in the diabetic rat model. The vascular permeability will be measured by the Evans blue-albumin and fluorescein-albumin leakage methods. The Phase I project will not only address the feasibility to use K5 eyedrops for the treatment of DME, but also generate essential data and lay a solid ground for the development of a marketable product in the Phase II studies. Our long-term goal is to develop a novel, noninvasive, effective therapy for DME.

Principal Investigator:

Kangmo Lu
4052714629
klu@ouhsc.edu

Business Contact:

Robert Mott
4054136290
RMOTT@OUHSC.EDU
Small Business Information at Submission:

Charlesson, Llp
Charlesson, Llp 7005 Trenton Rd Oklahoma City, OK 73116

EIN/Tax ID: 200088840
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No